VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
ASCO26: Ivonescimab Demonstrates 34% Overall Survival Improvement in First-Line Squamous NSCLC, Setting New Standard of Care
ASCO26: Ivonescimab Demonstrates 34% Overall Survival Improvement in First-Line Squamous NSCLC, Setting New Standard of Care
May 31, 2026 20:21 CST Updated 20:30
Share:
